Neuro Intercept™ is an investigational molecular diagnostics program applying the Intercept IQ™ platform to the early detection and biological monitoring of neurodegenerative disease. By integrating multi-omic biomarkers, advanced molecular analytics, and artificial intelligence, Neuro Intercept™ is being developed to identify biological changes that may precede clinical symptoms.
Powered by the Intercept IQ™ platform and under development by Kivara Neurosciences.
The Opportunity
Neurodegenerative diseases often begin years — even decades — before noticeable cognitive symptoms appear. Despite significant advances in treatment, many patients are still diagnosed only after substantial and irreversible neuronal damage has already occurred. Earlier identification of biological changes may create new opportunities for risk assessment, patient stratification, clinical research, and therapeutic intervention.
People worldwide are living with dementia.
World Health Organization
New cases of dementia are diagnosed globally each year.
World Health Organization
Alzheimer's disease accounts for approximately 60–70% of all dementia cases.
World Health Organization
The biological processes underlying neurodegeneration may begin long before clinical symptoms become apparent, creating a critical window for earlier investigation and intervention.
World Health Organization
Healthy neurons
Progressive neurodegeneration
Understanding the earliest molecular changes associated with neurodegeneration has the potential to reshape how neurological diseases are studied, monitored, and eventually treated. Neuro Intercept™ is being developed to support this next generation of precision neuroscience through the Intercept IQ™ molecular intelligence platform.
The Clinical Challenge
Many neurological diseases begin years — even decades — before clinical diagnosis. By the time cognitive impairment or neurological symptoms become apparent, substantial neuronal injury has often already occurred.
01Normal Brain
Healthy neuronal and glial biology.
02Silent Molecular Changes
Subclinical shifts in protein handling, energy metabolism, and cellular stress.
03Protein Misfolding
Aggregation of amyloid-β, tau, α-synuclein, TDP-43, and related species.
04Neuroinflammation
Microglial and astrocytic activation amplify injury.
05Neuronal Injury
Synaptic loss, axonal damage, and progressive cell death.
06Functional Decline
Subtle cognitive or neurological changes emerge.
07Clinical Symptoms
Diagnosis follows only after substantial injury.
Earlier biological insight may create opportunities for earlier intervention, improved monitoring, and more informed therapeutic development.
Neuro Intercept™ is an investigational molecular intelligence program designed to integrate multiple biological signals associated with neurodegeneration into a unified analytical framework. Rather than relying on a single biomarker, Neuro Intercept™ investigates complementary molecular pathways that may provide deeper insight into neurological disease biology.
Neurodegenerative diseases are complex, involving interactions between neuronal biology, inflammation, metabolism, genetics, and systemic physiology. Neuro Intercept™ is being developed to investigate these complementary biological dimensions through the Intercept IQ™ molecular intelligence platform, supporting future neuroscience research and precision medicine initiatives.
Neuro Intercept™ is an investigational research program under development by Kivara Neurosciences. The biomarkers and analytical framework shown represent areas of active scientific investigation and are not intended for clinical diagnosis or patient management.
Neuro Intercept AD
Neuro Intercept AD is being developed to investigate molecular biomarkers associated with Alzheimer's disease biology.
Biological Focus
Potential Applications
Neuro Intercept MS
Neuro Intercept MS is being developed to investigate molecular biomarkers associated with inflammatory and neurodegenerative processes in Multiple Sclerosis.
Normal Myelin
Intact myelin sheaths enable saltatory conduction.
Immune Activation
Autoreactive lymphocytes cross the blood–brain barrier.
Demyelination
Focal loss of myelin disrupts conduction.
Axonal Injury
Persistent inflammation drives axonal damage.
Disease Progression
Cumulative injury manifests as relapses and progression.
Potential Applications
Powered by Intercept IQ™
Multi-Omic Intelligence
Neurodegenerative diseases arise from the interaction of multiple biological systems rather than a single molecular pathway. Neuro Intercept™ integrates diverse molecular, cellular, inflammatory, metabolic, and clinical signals through the Intercept IQ™ platform to investigate the complex biology underlying neurological disease.
Rather than relying on a single biomarker, Neuro Intercept™ investigates complementary biological dimensions — including molecular biology, neuroinflammation, metabolism, genetics, proteomics, epigenetics, and clinical intelligence — to provide a more comprehensive understanding of neurodegenerative disease.
Designed for Translational Neuroscience
The Intercept IQ™ platform is engineered to integrate diverse biological datasets into a unified molecular intelligence framework, supporting biomarker discovery, patient stratification, longitudinal research, and future precision neuroscience initiatives.
Current Research Focus
Neuro Intercept™ is being developed to investigate molecular signatures associated with neurodegenerative disease through advanced blood-based diagnostics and the Intercept IQ™ platform. Current research focuses on understanding disease biology, supporting biomarker discovery, and enabling future precision neuroscience applications.
Investigating molecular signatures that may emerge during the earliest stages of neurodegenerative disease—before measurable cognitive symptoms become apparent—to better understand disease biology and identify opportunities for earlier scientific investigation.
Exploring how blood-based molecular biomarkers may be used to investigate biological changes longitudinally, supporting research into disease progression and the biological effects of emerging therapeutic interventions.
Supporting translational neuroscience by investigating biomarkers that may help researchers better understand biological responses to emerging neuroprotective and disease-modifying therapeutic approaches.
Integrating molecular, inflammatory, metabolic, genetic, and clinical information to support biomarker discovery, patient stratification, and future precision neuroscience research.
Neuro Intercept™ is an investigational research program designed to explore the complex molecular biology of neurodegenerative disease. By integrating multi-omic biomarkers, longitudinal data, and artificial intelligence through the Intercept IQ™ platform, the program aims to support future biomarker discovery, translational neuroscience, and precision research.
Neuro Intercept™ is an investigational research program under development by Kivara Neurosciences. The applications described represent areas of ongoing scientific investigation and are not intended to establish clinical performance or support patient diagnosis, treatment, or management.
Developed by Kivara Neurosciences · Powered by Intercept IQ™
Neuro Intercept™ is an investigational research program advanced by Kivara Neurosciences, built upon the Intercept IQ™ molecular intelligence platform — combining molecular diagnostics, multi-omic analysis, and artificial intelligence to investigate the biology underlying neurodegeneration.
Neuro Intercept™ is an investigational research program under development by Kivara Neurosciences. The Intercept IQ™ platform serves as the shared molecular intelligence framework supporting disease-specific biomarker discovery across multiple therapeutic areas. Neuro Intercept™ is not currently approved for clinical diagnosis or patient management.
Expanding the Future of Precision Neuroscience
The Intercept IQ™ platform was designed to extend beyond metabolic disease. Neuro Intercept™ represents the application of advanced molecular diagnostics, multi-omic intelligence, and artificial intelligence to the investigation of neurodegenerative disease.
